Invivogen
Menu

Anti-hCD20 isotype family

Anti-hCD20 comparative table | InvivoGen

InvivoGen's anti-hCD20 isotype family features the variable region of either Rituximab, Ofatumumab or Obinutuzumab clinical monoclonal antibodies (mAbs), which all target the human CD20 antigen (hCD20).
Our anti-hCD20 antibodies feature either native or engineered constant regions (Fc), which results in different capacities to exert biological functions such as complement dependent cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC), or apoptosis.

  • Rituximab is a type I (first generation) mouse/human chimeric IgG1 mAb.
  • Ofatumumab is a type I (first generation) fully human IgG1 mAb.
  • Obinutuzumab is a type II (second generation) non-fucosylated, fully humanized IgG1 mAb.

InvivoGen's anti-hCD20 antibodies are generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography according to their isotype (protein G for IgG, protein L for IgE and IgM, and peptide M for IgA).

Customer Service
& Technical Support
Contact us
Shopping cart is empty